Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Coiffier

Showing results (211-220 of 249) with videos related to

Pageof 25
Sort By:
British Journal of Haematology|November 27, 2013
Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosisClémentine Sarkozy, Lucile Baseggio, Pierre Feugier, et al.
The Lancet. Haematology|December 22, 2015
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 studyJehan Dupuis, Franck Morschhauser, Hervé Ghesquières, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA studyChristiane Copie-Bergman, Philippe Gaulard, Karen Leroy, et al.
Leukemia & Lymphoma|November 12, 2013
Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatmentJulien Lenglet, Catherine Traullé, Nicolas Mounier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup TrialPatrice Carde, Matthias Karrasch, Catherine Fortpied, et al.
The Lancet. Oncology|April 13, 2011
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trialFrédéric Peyrade, Fabrice Jardin, Catherine Thieblemont, et al.
The Lancet. Haematology|January 3, 2017
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA groupFrédéric Peyrade, Serge Bologna, Vincent Delwail, et al.
The Lancet. Haematology|July 18, 2017
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trialWon Seog Kim, Christian Buske, Michinori Ogura, et al.
British Journal of Haematology|September 17, 2013
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphomaBertrand Coiffier, John Radford, André Bosly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
Pageof 25

Showing results (211-220 of 249) with videos related to

Sort By:
Pageof 25
British Journal of Haematology|November 27, 2013
Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosisClémentine Sarkozy, Lucile Baseggio, Pierre Feugier, et al.
The Lancet. Haematology|December 22, 2015
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 studyJehan Dupuis, Franck Morschhauser, Hervé Ghesquières, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA studyChristiane Copie-Bergman, Philippe Gaulard, Karen Leroy, et al.
Leukemia & Lymphoma|November 12, 2013
Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatmentJulien Lenglet, Catherine Traullé, Nicolas Mounier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup TrialPatrice Carde, Matthias Karrasch, Catherine Fortpied, et al.
The Lancet. Oncology|April 13, 2011
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trialFrédéric Peyrade, Fabrice Jardin, Catherine Thieblemont, et al.
The Lancet. Haematology|January 3, 2017
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA groupFrédéric Peyrade, Serge Bologna, Vincent Delwail, et al.
The Lancet. Haematology|July 18, 2017
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trialWon Seog Kim, Christian Buske, Michinori Ogura, et al.
British Journal of Haematology|September 17, 2013
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphomaBertrand Coiffier, John Radford, André Bosly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
Pageof 25